Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Case Report

Volume 5, Number 5, October 2015, pages 299-303


Ipilimumab-Induced Hypophysitis May Not Affect All Pituitary Cell Lines: A Case Report

Figures

Figure 1.
Figure 1. MRI of the brain performed at the time of diagnosis of IH demonstrates soft tissue fullness of the pituitary with heterogeneous enhancement after contrast.
Figure 2.
Figure 2. MRI of the brain 3 months later demonstrates resolution of the pituitary enhancement with appearance of an empty sella.

Table

Table 1. Laboratory Investigations
 
Laboratory investigationsPrior to ipilimumabAt diagnosis of IHAt 5-month follow-upAt 8-month follow-upAt 14-month follow-upReference range
Total testosterone (ng/dL)Not tested11< 10165150241 - 827
TSH (μIU/mL)0.880.090.06Not tested0.090.28 - 3.89
Free T4 (ng/dL)1.191.151.5Not tested0.830.58 - 1.64
Total T3 (ng/dL)10174Not testedNot testedNot tested97 - 178
AM Cortisol (μg/dL)Not tested0.091.4Not tested0.96.7 - 22.6
ACTH (pg/mL)Not testedNot tested< 5Not tested5< 46
ACTH stimulation test (μg/dL)Not testedNot tested1.4, 9.2, 11.4Not testedNot tested≥ 18
Prolactin (ng/mL)Not testedNot tested0.6Not tested0.72.6 - 13.3
IGF-1 (ng/dL)Not testedNot tested40Not testedNot tested17 - 246
LH (mIU/mL)Not testedNot tested1.4Not testedNot tested1.2 - 8.6
Serum osmolality, urine osmolality and serum electrolytesWithin normal rangeWithin normal rangeWithin normal rangeWithin normal rangeWithin normal range